Brief: Solid Biosciences Inc - Company Ends 2022 With Approximately $213.7 Million In Cash And Investments Anticipated Cash Runway Into 2025
23/03/2023 13:13
March 23 (Reuters) - Solid Biosciences Inc SLDB.O :
* SOLID BIOSCIENCES INC - COMPANY ENDS 2022 WITH
APPROXIMATELY
$213.7 MILLION IN CASH AND INVESTMENTS; ANTICIPATED CASH RUNWAY
INTO 2025
* SOLID BIOSCIENCES INC - REMAINS ON TRACK TO SUBMIT IND FOR
SGT
003, A NEXT-GENERATION GENE THERAPY FOR PATIENTS WITH DUCHENNE
* SOLID BIOSCIENCES INC - NET LOSS FOR Q4 OF 2022 WAS $15.2
MILLION, COMPARED TO $18.6 MILLION FOR Q4 OF 2021
Source text for Eikon: ID:nGNX4ZW3X1
Further company coverage: SLDB.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Solid Biosciences
See all newsSolid Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Solid Biosciences Q2 net loss widens on higher R&D costs
Marketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs